The Innate Immune System of the Perinatal Lung and Responses to Respiratory Syncytial Virus Infection by Derscheid, Rachel J. & Ackermann, Mark R.
Veterinary Pathology Publications and Papers Veterinary Pathology
9-2013
The Innate Immune System of the Perinatal Lung
and Responses to Respiratory Syncytial Virus
Infection
Rachel J. Derscheid
Iowa State University, rdersch@iastate.edu
Mark R. Ackermann
Iowa State University, mackerma@iastate.edu
Follow this and additional works at: http://lib.dr.iastate.edu/vpath_pubs
Part of the Veterinary Pathology and Pathobiology Commons
The complete bibliographic information for this item can be found at http://lib.dr.iastate.edu/
vpath_pubs/57. For information on how to cite this item, please visit http://lib.dr.iastate.edu/
howtocite.html.
This Article is brought to you for free and open access by the Veterinary Pathology at Iowa State University Digital Repository. It has been accepted for
inclusion in Veterinary Pathology Publications and Papers by an authorized administrator of Iowa State University Digital Repository. For more
information, please contact digirep@iastate.edu.
The Innate Immune System of the Perinatal Lung and Responses to
Respiratory Syncytial Virus Infection
Abstract
The response of the preterm and newborn lung to airborne pathogens, particles, and other insults is initially
dependent on innate immune responses since adaptive responses may not fully mature and require weeks for
sufficient responses to antigenic stimuli. Foreign material and microbial agents trigger soluble, cell surface, and
cytoplasmic receptors that activate signaling cascades that invoke release of surfactant proteins, defensins,
interferons, lactoferrin, oxidative products, and other innate immune substances that have antimicrobial
activity, which can also influence adaptive responses. For viral infections such as respiratory syncytial virus
(RSV), the pulmonary innate immune responses has an essential role in defense as there are no fully effective
vaccines or therapies for RSV infections of humans and reinfections are common. Understanding the innate
immune response by the preterm and newborn lung may lead to preventive strategies and more effective
therapeutic regimens.
Keywords
innate immunity, lung, respiratory syncytial virrus (RSV), pneumonia
Disciplines
Veterinary Pathology and Pathobiology
Comments
This is an author's accepted manuscript of an article from Veterinary Pathology 50 (2013): 827–841,
doi:10.1177/0300985813480216. Posted with permission.
This article is available at Iowa State University Digital Repository: http://lib.dr.iastate.edu/vpath_pubs/57
The Innate Immune System of the Perinatal Lung and 
Responses to Respiratory Syncytial Virus Infection 
 
Rachel J. Derscheid1, Mark R. Ackermann1* 
1 Department of Veterinary Pathology, 2738 College of Veterinary Medicine, Iowa 
State University, Ames, Iowa 50011, USA; rdersch@iastate.edu; 
mackerma@iastate.edu 
* Author to which correspondence should be addressed; mackerma@iastate.edu; 
Tel.: 515-294-3647; Fax: 515-294-5423 
  
ABSTRACT: 
The response of the preterm and newborn lung to airborne pathogens, particles and other 
insults is initially dependent upon innate immune responses since adaptive responses may 
not fully mature and require weeks for sufficient responses to antigenic stimuli.  Foreign 
material and microbial agents trigger soluble, cell surface and cytoplasmic receptors which 
activate signaling cascades that invoke release of surfactant proteins, defensins, interferons, 
lactoferrin, oxidative products and other innate immune substances that have antimicrobial 
activity which can also influence adaptive responses.  For viral infections such as respiratory 
syncytial virus (RSV) the pulmonary innate immune responses has an essential role in 
defense as there are no fully effective vaccines or therapies for RSV infections of humans 
and reinfections are common.  Understanding the innate immune response by the preterm 
and newborn lung may lead to preventive strategies and more effective therapeutic 
regimens. 
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INTRODUCTION 
Wiith the first breath after birth the lung is exposed to a wide variety of airborne substances 
and microbial agents.  Despite this, most newborns do not develop extensive pulmonary 
inflammatory/immune responses which would impair airflow and gaseous exchange.  This is 
due, at least in part, to the innate immune system’s clearance of particulate matter and 
discrete handling of other substances and microbial agents.  The response to pathogens 
and foreign material, vapors, fluids, aerosols, mists, and other substance by the perinatal 
lung is especially dependent upon innate immune responses since adaptive immune 
responses are not fully mature and can require weeks for sufficient responses to antigenic 
stimuli.  The innate immune system of the lung includes the mucociliary apparatus, air-
surface liquid and its contents, epithelia, serum products, dendritic cells and other 
leukocytes (Fig. 1).  Foreign material and microbial agents trigger soluble, cell surface and 
cytoplasmic receptors which activate signaling cascades that trigger release of surfactant 
proteins, defensins, interferons, lactoferrin, oxidative products and other innate immune 
substances that have antimicrobial activity and can also invoke adaptive responses.  For 
viral infections such as respiratory syncytial virus (RSV), innate immune responses are 
increasingly appreciated for their role in reducing disease severity.  RSV is a common 
respiratory pathogen world-wide and can cause severe bronchiolitis and respiratory disease 
resulting in hospitalization in infants (especially preterm), immunosuppressed individuals 
and the elderly (21, 95).  Each of these categories of people has less than optimal adaptive 
immune responses and thus innate immune responses become even more vital since there 
are no approved vaccines or fully satisfactory therapies.  Vaccine development for RSV in 
humans has been hindered by deaths that occurred in RSV infected infants previously 
vaccinated with a formalin-inactivated vaccine in a trial in the 1960’s (21).  Although RSV is 
a ubiquitous virus and most all women have circulating antibodies, preterm infants may have 
a limited amount maternal antibody because the shortened gestational time of an infant born 
preterm reduces the amount of time for transplacental passage of maternal immunoglobulin.  
Therefore, some preterm infants have limited maternal antibody, their immune system has 
not ever been exposed to RSV or many other antigens, and their adaptive immune system 
is not fully mature.  Such individuals are heavily dependent upon their innate immune 
response for protection against severe RSV infection.  Also, RSV and other viruses such as 
influenza, infect bronchiolar epithelial cells and once infected become inflamed impairing 
airflow and thus the gaseous exchange function of the lung.  Reducing bronchiolar epithelial 
cell infection is vital, especially for RSV since there are no fully satisfactory therapies or 
approved vaccines.  Cattle and sheep are also susceptible to RSV infections especially 
during times of stress as can occur with shipping, weaning, overcrowding, poor 
management, and improper environmental and housing conditions.  Such stress can also 
impair adaptive and innate immune responses leading to increased susceptibility.  Our 
laboratory has developed a lamb model of RSV infection that closely mimics key features of 
RSV infection in newborn infants (23).  This review addresses key features of the respiratory 
innate immune system of the perinatal lung comparing newborn and adult.  It highlights 
responses to one specific virus, RSV, which is a serious and common pathogen of infants, 
cattle, and sheep. 
 
Components of the innate immune system and responses to RSV 
 
The newborn lung is challenged by foreign material and airborne stimuli that can invoke 
cellular responses.  The molecular machinery of receptor recognition, signaling, activation or 
suppression of transcription factors, mRNA transcription, translation, protein translocation 
and activity is triggered to a newly experienced level by the various lung cell types while the 
lung itself transitions to its primary function: gaseous exchanges.  This dynamic activity is 
even more complicated in newborns that are preterm or premature and also in those with 
physiologic stress, inherited disorders or pathologic conditions.  Investigations of the 
perinatal lung of human infants have limitations in monitoring and measuring cytokine, 
chemokine, cellular, and humoral responses, particularly localized responses.  The methods 
used must generally be minimally invasive, which limits the amount and type of data that 
can be collected from the pulmonary response to microbial agents.  Additionally, variations 
in disease diagnosis as well as method of sample collection create difficulties in 
comparisons between studies. Despite these challenges, much has been learned from 
human subjects and while knowledge gaps are addressed in a wide variety of animal 
models. 
In perinatal, maturing and adult lungs, the initial diseases or stresses caused by viruses, 
other microbial agents and their products, antigens, allergens, foreign material, vapors and 
substances arriving in the lung via the vasculature have an acute onset and typically a fairly 
short duration, although there can be protracted or recurring symptoms, depending on the 
inciting stimulus.  Minimal or mild exposure of these insults is handled every moment by the 
pulmonary tract of healthy individuals without incident.  Because airflow and gaseous 
exchange are optimal in non-inflamed lung, it is beneficial for the inflammatory response to 
be as minimal and rapid as possible.  Mucociliary clearance and physiologic activity of 
innate immune products secreted onto the air-surface liquid (ASL) are of special importance 
in this regard to avoid/reduce epithelial cell damage, bronchoconstriction, vascular leakage 
and an overt inflammatory or adaptive response.  There is a range of responses by 
individuals and severity of disease, with some individuals at increased risk due to altered 
lung structure or function and potentially a reduced ability to develop an adaptive response 
compared to others that typically experience mild disease.  Such variations between 
individuals range from differences in gross structure (e.g., diameter of the nasal meatus or 
length of the trachea), epithelia (e.g., numbers and distribution of goblet cells); immune 
(e.g., distribution of dendritic cells or mast cells) and genetic (e.g., single nucleotide 
polymorphisms and gene copy number of cytochrome P450 isoenzymes, defensins, or 
surfactant proteins A and D). 
The physical innate barriers of mucous production, mucociliary elevator apparatus, 
submucosal gland secretions, and complex branching of the respiratory tree must initially be 
overcome by microbial agents such as RSV to reach bronchiolar epithelium and respiratory 
airways where the virus establishes infection and replicates (98).  Once a virus, microbial 
product, allergen, antigen or foreign material deposits onto the mucosal surface of the 
respiratory airways, it comes in contact with the mucosal secretions and the air-surface 
liquid (ASL).   
In trachea, bronchi, and to some degree the bronchioles, the mucosal secretory layer of 
these airways is composed of periciliary sol and gel layers of the mucociliary apparatus 
formed from secretions from goblet cells, submucosal glands, and respiratory epithelial cells.  
The periciliary sol layer contains water that accumulates with chloride released from nearby 
epithelial cells, submucosal glands, and serous cells.  The sol layer contains tethered 
mucins that form a “brush” layer on which the overlying mucus layer sits (18).  The sol (also 
termed “ciliary brush”) layer allows cilia beat activity maintained in the proper pH and the 
amount of water in the sol layer is regulated by sodium (Na+) resorption by epithelial Na+ 
channels (ENaC).  With dehydration, the sol (ciliary brush) layer becomes thinner and the 
tethered mucins aggregate both of which decrease ciliary beat.  Certain other conditions 
such as cystic fibrosis and chronic obstructive pulmonary disease (COPD) can alter the 
consistency of the sol (ciliary brush) layer (18).  The gel layer is composed of mucin 
glycoproteins encoded by 22 MUC genes of which 16 have been identified in the human 
lung including MUC1, MUC2, MUC4, MUC5AC, MUC5B, MUC7, MUC8,  MUC MUC11, 
MUC13, MUC15, MUC 16, MUC 18, MUC 19, MUC20, MUC 21, MUC22.  These proteins 
are linked to oligosaccharides and localize along the apical epithelial surface, some in a 
secreted form, others tethered to the cell membrane.  Some, such as MUC5AC are secreted 
by goblet cells, while others, such as MUC5B are secreted from mucus cells and 
submucosal glands (64).  MUC1 is membrane-tethered and expressed by lung epithelial 
cells, including type II cells (64), and has anti-inflammatory properties through inhibition of 
Toll-like receptor (TLR) signaling.  With RSV infection, mucin production is regulated by 
TLR7, IL-17 and IL-23 (85).  Expression of MUC genes can be altered by acute disease 
conditions such as preterm birth, dehydration, heat, smoke and particular matter and chronic 
conditions such as allergic conditions, chronic obstructive pulmonary disease (COPD), 
recurrent airway obstruction (horses), toxins (e.g, bleomycin), chronic infections, cystic 
fibrosis, and primary or metastatic neoplasia (18, 64).   
Ciliary beat moves the pericellular ASL in an anterior direction in healthy individuals and 
various rates which can be measured.  Certain disease conditions, such primary ciliary 
dyskinesia (immotile ciliary syndrome; Kartagener Syndrome), exposure to certain toxins 
(e.g., ethanol, cigarette smoke), infectious agents (e.g., Mycoplasma sp.) can drastically 
reduce ciliary activity and thus impair physical clearance of the materials trapped within the 
ASL.  Other conditions, such as cystic fibrosis and severe dehydration alter the hydration 
level of the ASL resulting in increased viscosity and a thick, mucinous layer that is not 
adequately propelled in an anterior direction by the cilia (18).   
Submucosal glands are present in the nasal cavity, trachea, and bronchi of humans, cattle, 
sheep, and pigs; however, in rodents submucosal glands are limited to the upper airways 
(17, 64).  Submucosal glands work in concert with respiratory epithelium to create an 
oxidative host defense system at the mucosal surface through production of secretory 
products that contribute to the mucosal gel and sol layers.  Submucosal glands produce 
lactoperoxidase (LPO) which works in concert with other enzymes and molecules to form 
oxidative radicals within the ASL that contribute to antimicrobial defense.  Airway epithelia 
adjacent to submucosal glands transport thiocyanate (SCN-) to the epithelial surface and 
also produce hydrogen peroxide (H2O2) via intracellular dual oxidases (Duox) (22, 38, 142).  
LPO secreted by the submucosal glands onto the air-surface liquid catalyzes the conversion 
of H2O2 and SCN- to oxythiocyanate (OSCN-).  The Duox/LPO system has microbicidal 
activity against multiple bacteria and viruses (22, 142).  In vitro assays that substitute I- for 
SCN- in the LPO/Duox system have shown killing of RSV to the same level of bleach (37).  
Submucosal glands also secrete lactoferrin and lysozyme, two important factors in innate 
immunity, especially in the air-surface liquid ASL.  Lactoferrin is an antimicrobial 
glycoprotein that not only binds pathogens directly, but acts as an immunomodulatory 
protein and bridges the innate-adaptive immunity crossover (73-75).  Pneumocytes (alveolar 
type I cells) make minor contributions to the amount of lactoferrin and lysozyme present in 
ASL (27).   
Tracheal, bronchial, and bronchiolar epithelial cells have an active role in immunity through 
the secretion of immunomodulatory compounds with innate antimicrobial activity, as well as 
secretion of cytokines and chemokines upon infection to recruit immune cells.  Epithelial 
cells produce innate immune molecules with anti-RSV activity.  Surfactant proteins A and D 
(SP-A and SP-D, respectively) are collectins that bind pathogens with the globular head 
region (mannose-binding C-type lectin) and signal with the collagen-like tail.  Both SP-A and 
SP-D are produced and secreted into the airway by primarily type II epithelial cells with a 
lesser contribution by Clara cells.  SP-A and SP-D are reduced in infants with RSV disease 
that require ventilator assistance (62).  In cultured cell studies, SP-A and SP-D mRNA 
expression is increased by RSV infection, but protein expression is decreased, putatively 
through decreased translational efficiency (16).  SP-A binds mannose residues of microbial 
agents and to RSV F protein resulting in increased viral clearance (77, 117).  SP-D 
enhances phagocytosis and clearance of RSV in a mouse model (76).  Both SP-A and SP-D 
enhance RSV elimination (43).  Genetic polymorphisms in SP-A or SP-D are associated with 
altered severity of RSV infection (3, 28, 69), underscoring the essential role of these 
collectins in anti-viral defense.  Expression of SP-A and SP-D increases throughout fetal 
lung development in lambs (91, 133).  RSV infection of lambs enhances expression of SP-A 
and SP-D and is associated with viral clearance (44, 61, 101, 102).  Drugs, such as ethanol 
exposure in utero, reduce SP-A production in lungs of newborn and may explain, at least in 
part, why ethanol consumption by pregnant mothers is a risk factor for severe RSV disease 
(72). 
There are many other proteins produced by respiratory epithelia that contribute to innate 
defense; however, often their activity and function is not completely defined (Tables 1, 2).  
Secretory leukocyte protease inhibitor (SLPI) is a serine antiprotease and as such protects 
the lung against enzymes released from neutrophils and other leukocytes but SLPI also has 
antimicrobial and antiviral activity (118, 139).  Palate, lung and nasal epithelium (PLUNC) 
proteins are produced at high levels by upper respiratory epithelia and have homology to 
lipopolysaccharide (LPS) binding protein and bacterial/permeability-increasing protein (BPI) 
suggesting a role for PLUNC in LPS binding (118, 139).  BPI protein can bind LPS and also 
has bactericidal activity against Gram-negative bacteria.  Ribonuclease 7 (RNase 7) has 
been identified in skin epithelia (and thus, is likely also present in the stratified squamous 
epithelium of the anterior nasal meatus) and has potent bactericidal activity.  Lipocalin (also 
known as neutrophil gelatinase-associated lipocalin) can bind bacterial siderophores (118). 
Beta defensins are antimicrobial cationic peptides also produced by respiratory epithelium, 
including pneumocytes and submucosal glands (95, 118, 139) of many species, including all 
domestic animals, rodents, and avian species.  The beta defensins have direct antimicrobial 
activity against a wide-variety of microbial pathogens, and also have numerous other 
functions including leukocyte and dendritic cell chemotaxis, epithelial proliferation, mast cell 
degranulation, and immunomodulatory activity.  Human beta defensins (HBD) 1-4 are 
produced in the respiratory tract.  HBD-1 is constitutively expressed while HBD2-4 are 
inducible (52).  In vitro infection of lung epithelia induces HBD-2 production by TNF-α via a 
nuclear factor κβ (NF-κβ)-dependent mechanism.  Secreted HBD-2 then disrupts the viral 
envelope, interfering with viral entry into host cells (65).  Alpha defensins are produced by 
neutrophils and enterocytes, including Paneth cells, and theta defensins are present in 
some non-human primates but are a pseudogene in humans.  Similar to the beta defensins, 
the human cathelicidin LL37 is a cationic antimicrobial peptide (139).  LL37 is stored in 
neutrophils and produced by other leukocytes as well as respiratory epithelium at a low 
level.  LL37 can be up-regulated in disease and plays a role in direct microbial killing as well 
as in immunomodulation and apoptotic signaling (8, 13, 81, 139).  Sheep produce a 
cathelicidin, SMAP29 which has potent anti-bacterial activity and sheep also express sheep 
beta defensin-1 (SBD-1) which increases with paramyxoviral infection (RSV is a 
paramyxovirus) and is associated with viral clearance (15). 
Clara cells are non-ciliated bronchiolar epithelial cells with multiple roles in the airways.  
Clara cells biometabolize xenobiotics (19), secrete immunomodulatory substances (128), 
and act as progenitor cells (11).  Just as type II pneumocytes serve as a proliferation pool to 
replace dead and damaged type I pneumocytes, Clara cells act as a progenitor for type II 
cells, forming a proliferation pool that is vulnerable to exhaustion, especially in neonates 
(123, 124), but also in chronic smokers (chronic toxin exposure) (14).  Further, damage to or 
dysfunction of Clara cells creates a proinflammatory environment due to the loss of their 
immunomodulatory secretions (29). In their immunomodulatory capacity, Clara cells secrete 
a unique protein: Clara cell secretory protein (CC10), also known as CCSP, CC16, 
secretoglobin, and uteroglobin.  CC10 expression is increased throughout ontogeny (Fig. 2) 
and CC10 levels in BALF and serum during acute injury such as smoke inhalation or 
application of pneumotoxicants (naphthalene, 4-ipomeanol), but decreased in chronic or 
dysplastic airway dysfunction, such as asthma, COPD, or bronchopulmonary dysplasia 
(BPD) (112).  Infants that developed BPD had lower levels of CC10 at birth than age-
matched infants that did not develop BPD (112).  Gene knockout studies performed in mice 
have shown increased inflammation and viral persistence in CC10-deficient mice when 
challenged with RSV; restoration of CC10 abrogated these effects (141). Amniotic levels of 
CC10 during mid-trimester were significantly higher in women who had preterm premature 
rupture of membranes compared to women who did not, and this elevation of CC10 could 
be in response to a proinflammatory event (106). While CC10 is the most studied secretion 
of Clara cells, Clara cells also produce SP-A and SP-D (100, 128).  Clara cell cytochrome 
P450 enzymes such as CYP1A1 and CYP1A2 detoxify inhaled compounds and compounds 
entering the lung hematogenously.  This is beneficial for some toxins; however, a toxic 
metabolite, 3-methylindololamine is a toxic metabolite formed by Clara cell metabolism of 3-
methyl indole.   
Type II cells of lung increase in number and distribution and also differentiate progressively 
in developing ovine fetal lung (17, 89, 91) and lungs of other animals.  Type II cells 
proliferate to replace themselves and also differentiate into type I cells that line pulmonary 
alveoli.  Type I cells produce surfactant, surfactant proteins A, B, C, and D, and also a 
myriad of innate immune products including defensins, cathelicidins, lactoferrin and also 
other inflammatory mediators such chemokines, interferons, and cytokines.  Once infected 
with RSV, type II cells of term lambs have increased expression of SP-A, SP-D and SBD-1; 
expression of these genes is reduced in RSV infected type II cells of preterm lambs and 
may, in part, explain the increased susceptibility and disease severity of preterm lambs and 
infants to RSV infection (61). 
Proteoglycans of the extracellular matrix can also regulate pulmonary inflammation and the 
innate immune response.  Proteoglycans consist of a protein backbone attached to a 
glycosaminoglycan (GAG) side change.  In the lung, GAGs include: hyaluronan (14%), 
chondroitin sulfate/dermatan sulfate (31%), heparin sulfate (40-60%)/heparin (5%) and 
keratan sulfate (<2%) (42).  In the lung, the three families of extracellular matrix 
proteoglycans include large aggregating chondroitin sulfate proteoglycans (CSPG), small 
leucine-rich CSPGs, and heparan sulfate proteoglycans (HSPG).  Perlecan, a HSPG is 
present in the basal lamina; versican and decorin (CSPGs) are present in interstitial spaces; 
while syndecans are membrane proteoglycans.  These proteoglycans and GAGs bind to 
numerous cytokines, chemocines and growth factors sequestering the molecules in a latent, 
inactive state.  These include CXC chemokines (CXCL1-4, CXCL8, CXCL10, CXCL12), CC 
chemokines (CCL2-5, CCL11), proinflammatory cytokines (IL-1α and β, IL-2, IL-5, IL-6, IL-7, 
IL-12, TNFα, IFNɣ), anti-inflammatory cytokines (IL-4, IL-10), and growth factors (fibroblast 
growth factors, vascular endothelial growth factor (VEGF), GM-CSF, and TGFβ) (42).  With 
inflammation and release of enzymes such as many of the matrix metalloproteinases, these 
inflammatory mediators can be released and become active modifying the inflammatory 
response, including leukocyte adhesion molecules and regulating both the innate and 
adaptive immune responses. 
Further triggering of innate immune responses by RSV 
If a virus such as RSV, another microbial agent or its product, an allergen or foreign material 
surpass the ASL and its contents, they can come in contact with the apical surface of 
epithelial cells of the lower airway (98).  Once epithelial cells are infected and damaged by 
RSV, the blood-gas exchange is compromised due to cell degeneration, altered cell 
physiologic activity, and altered airflow through the airways due to intraluminal accumulation 
of necrotic cell debris, mucin, vascular fluid, and airway constriction.  Infected epithelial cells 
are not passively dependent upon rescue by leukocytes, but the epithelial cells themselves 
have an active role in modulating the immune response as well as the release of anti-RSV 
compounds such as SP-A and inflammatory mediators and interferons that prevent viral 
replication.  Such responses by epithelial cells are initially triggered by activation of pattern 
recognition receptors (PRRs), many of which are Toll-like receptors (TLRs).  TLRs are highly 
conserved molecules that recognize pathogen-associated molecular patterns (PAMPs) 
common to many general groups of pathogens and classes of microbes.  PRRs activated by 
RSV include TLR-4 (47, 64), TLR-2 (96), TLR-6, TLR-3, and retinoic acid-inducible gene I-
like receptor (RIG-I) (83).   
TLR-4 is a cell-surface molecule associated with CD14 that recognizes lipopolysaccharide 
(LPS) from Gram-negative bacteria and lipoteichoic acid from Gram-positive bacteria, as 
well as the F protein of RSV and other PRRs (39, 51, 68, 95).  The F protein of RSV 
activates TLR4 through binding of MD-2 protein and this can be inhibited by Lipid A analog 
antagonists (111).  Binding of the TLR-4/CD14 complex activates NF-κβ, eventually leading 
to secretion of IL-8, IL-10, IL-6, as well as increased expression of TLR-4 on epithelial cells 
(39, 68).  There is scientific dispute over the impact of two TLR-4 single nucleotide 
polymorphisms (SNPs) in regards to RSV disease severity.  Multiple studies found that a 
single SNP or a haplotype with two SNPs in the TLR-4 gene is associated with increased 
susceptibility to symptomatic RSV infection and premature birth (7, 109), while other studies 
had contrary findings (26, 84, 105).  Two dissenting articles examined a single SNP as 
opposed to the two-SNP haplotype.  The third looked at immune response to RSV in 7-9 
year olds’ peripheral blood monocytes, as opposed to comparing epidemiologic RSV 
disease to the haplotype.   
TLR-2 and TLR-6 form a cell-surface heterodimer (95).  Binding of TLR-2 activates NF-κβ 
through a MyD88-dependent pathway, initiating production of interleukin 1-beta (IL-1β) 
(119).  Studies in knockout mice demonstrate TLR-2 and -6 signaling in leukocytes that 
stimulates an immune response to RSV (96). 
TLR-3 is an intracellular TLR, present on the endosomal surface and recognizing dsRNA 
(95).  RSV is a single stranded RNA virus, but in vitro studies have demonstrated that TLR-3 
is activated during replication (pairing of template and daughter strands) and leads to 
increased CCL-5 (Regulated on Activation Normal T cells Expressed and Secreted 
(RANTES)) production (116).  Downstream signaling typically leads to interferon alpha and 
beta (IFNα and IFNβ) transcription.  In lambs, TLR 3, 4, 7, and 8 are differentially expressed 
during fetal development (133). 
RIG-I is an intracellular helicase that binds noncapped 5’ triphosphated RNAs and 
subsequently activates interferon regulatory factors 3 and 7 (IRF3 and IRF7) which are 
transcription factors for IFNα and IFNβ (95).  Recently, nucleolin has been shown to be an 
important cellular receptor for RSV (136) F protein.  After RSV enters  lung epithelial cells, 
RIG-I is activated and upregulates CCL-5 and interferon-inducible protein (IP10) in addition 
to IFN-β (83). Melanoma differentiation associated gene-5 (MDA-5) is also a helicase that 
recognizes ds RNA released from some viruses.  Both RIG-I and MDA-5 activated NF-
kappa B, IRF-3 and -7 via mitochondrial antiviral signaling adaptor (MAVS), interferon beta 
promoter stimulator (IPS-1), virus-inducing signaling adaptor, and Cardif.  Nucleotide-
binding domain, leuckine-rich repeat (NOD)-like receptors can also detect viral, bacterial and 
other pathogens that enter the cytoplasm through the leucine-rich repeat domains.  Over 20 
NOD-like receptors have been identified.  Some, such as NAPLP3, IPAF, and NALP1 
activate the inflammasome in macrophages and other cell types resulting in caspase 1 
activation of IL-1 beta and IL-18.  Endogenous molecules such as heat shock proteins 60 
and 70, urates, and adenosine activate epithelial cells, leukocytes, endothelial cells and 
other cell types in the lung.  These endogenous substances are termed danger-associated 
molecular patterns (DAMPs) or alarmins.  DAMPs activate inflammatory transcription 
factors; however, their signaling is modulated by simultaneous binding to CD24, which 
interacts with Siglec, a regulator of NF-kappa B. 
Many viral PRRs describe induce upregulation of type I interferons, IFN-α and IFN-β.  Many 
cell types in lung produce Type I interferons but plasmacytoid dendritic cells (pDCs; 
CD123+, CD303+, CD304+), which are present in lung, produce large amounts of IFN-α and 
lesser amounts of IFN-β after stimulation.  Type I interferons reduce viral replication in cells, 
typically through JAK-STAT pathways, as well as by upregulating MHC I, thereby indirectly 
promoting the killing of virus-infected cells (48, 49, 67, 95); also by production of down-
stream IFN products such as protein kinase R that disrupts viral translation (107), 2’,5’-
oligoadenylate synthetase 1 (OAS1) that activates an RNase L to cleave viral RNA (67), 
ISGylation that inhibits viral replication (49), and MxA protein that binds viral nucleoprotein 
to prevent replication and transcription (48).  Unlike other myxoviruses, RSV is resistant to 
MxA protein, although there are increased levels of MxA in peripheral blood of RSV-infected 
children (6, 20, 48).  RSV’s nonstructural proteins NS1 and NS2 disrupt interferons through 
IFN regulatory factor-3 (IRF-3).  NS1 protein inhibits IFN transcription and NS2 disrupts IFN 
signaling in the target cell (135).  A similar disruption of type I interferons by NS1 and NS2 
working in concert at multiple points in the IFN pathway occurs in bovine RSV infection 
(123).  Since two of the 11 proteins of RSV aim to disable the interferon system, there may 
be therapeutic potential in counteracting the action of NS1 and NS2 to allow the immune 
system to better control RSV.  RSV infection also decreases IFNβ (as well as IL-10 and 
TGF- β) in term lambs (131).  Type III interferons (interferon λ (lambda)) have been 
described and include IFNλ 1, 2, and 3 (also termed IL-29, IL-28A, and IL-28B, 
respectively).  These interferons signal through IL-10R2 and IFNLR1; however, their 
function is still being fully elucidated.   
Interferon gamma (IFN-γ) is a type II interferon and considered a Th1 cytokine, primarily 
produced by CD4+ T cells to activate macrophages, but in early RSV infection it is produced 
by natural killer (NK) cells, dendritic cells, and macrophages (95).  TGF-β and IL-10 regulate 
IFN-γ by reducing IFN-γ expression and functional activity (95).  Such reductions in IFN-γ 
expression affect viral infection since IFN-γ inhibits viral replication and increases MHC I and 
MHC II cell surface expression as well as increasing transcription of MHC I-associated 
peptides involved in antigen processing.  Also, stimulation of macrophages by IFN-γ induces 
secretion of IL-1, IL-6, IL-8, and TNF-α (41).  IFN-γ has been associated with increased 
CC10 protein and there is evidence of its involvement in regulation at the transcriptional 
level (113).  Low IFN-γ in nasopharyngeal secretions has been associated with increased 
disease severity in RSV-infected infants (127).  This may indicate a skewing toward a Th2-
type response as stimulation of immature lung macrophages with IFN-γ reduced RSV titers in 
mice (31).  IFN-γ is increased in term lambs infected with RSV and yet further increased in 
preterm lambs (over that of term lambs) (131, 132). 
IL-1β, IL-6 and TNF-α are proinflammatory cytokines produced by macrophages and 
epithelial cells that act to increase acute phase protein production from the liver, recruit 
neutrophils, and activate complement.  A direct relationship has been demonstrated 
between IL-1β levels in pharyngeal secretions and severity of RSV disease (82).  Infection 
of healthy adults’ dendritic cells with RSV stimulates IL-1β production and secretion, as well 
as the proinflammatory cytokines TNF-α and IL-6 (45).  And high levels of TNF-α and IL-1β 
are present in infants with RSV bronchiolitis (46, 88).  TNF-α levels are increased in preterm 
lambs infected with RSV compared to term lambs (131). 
Interleukin 8 (IL-8; CXCL-8), is a chemoattractant for neutrophils, basophils, and T cells that 
is secreted by monocytes, macrophages, fibroblasts, keratinocytes, and endothelial cells 
(93).  IL-8 is increased in nasal wash secretions of infants 1-6 months old infected with RSV, 
and this increase is more pronounced in those with more severe disease (71).  In the same 
study IL-8 levels were correlated with an increased required duration of supplemental 
oxygen as well as higher peak fractional inspired oxygen (71).  In a study comparing term to 
preterm infants that experienced RSV infection before six months of age a similar correlation 
between clinical severity score and IL-8 was found, but not in preterm infants (14).  This 
highlights the complexity of understanding how the immune response contributes to disease 
in infants.  As previously mentioned, signaling through TLR-4 via NF-κβ is one mechanism 
leading to increased IL-8 (68).  IL-8 is increased significantly also in lambs infected with 
RSV and likely contributes to the neutrophil infiltration into bronchioles of RSV-infected 
lambs and infants (131, 132). 
Interleukin 10 (IL-10) is primarily produced by leukocytes, particularly monocytes, and 
overall has a dampening effect on cellular recruitment through downregulation of class II 
MHC molecules and downregulation of Th1 cytokine production (95).  IL-10 is increased in 
nasal wash secretions of infants during RSV infection (94).  Intriguingly, elevated IL-10 
during acute RSV infection is associated with post-bronchiolitis wheeze (126).  
Heterozygosity of a SNP in the IL-10 gene was associated with a decreased incidence of 
severe RSV, but not associated with any difference in the incidence of post-bronchiolitis 
wheeze (56, 126).  IL-10 expression is decreased in term lambs infected with RSV (132). 
TGF-β has a mixed effect on the immune response, activating neutrophils and typically 
inhibiting macrophage activation, although TGF-β does have the ability to activate or 
deactivate macrophages and monocytes depending on the rest of the cytokine milieu (5, 
95).  TGF-β is produced by NK cells and macrophages in innate immunity as well as T and 
B cells as part of the adaptive immune response (54, 134, 140).  Proliferation and 
differentiation of CD4+ T cells is blocked by TGF-β, which may be associated with a general 
dysregulation of Th1/Th2 response in infants (138).  TGF-β also plays a role in 
immunoglobulin production and class switching (134). With RSV infection, TGF-β 
expression is decreased in term lambs (132).  
Macrophage inflammatory protein-1 (MIP) is a 4 member family of CC chemokines: MIP-1α 
(CCL3), MIP-1β (CCL4), MIP-1δ (CCL9/10), MIP-1γ (CCL15) (89).  MIPs are expressed by 
lymphocytes, monocytes or macrophages, and epithelial cells and are generally 
proinflammatory, recruiting macrophages (89).  MIP-1α and MIP-1β are the most thoroughly 
studied and well-characterized of the MIPs.  Murine and in vitro studies show that MIP-1α 
expression is increased in RSV infection (12, 25, 47, 103).  MIP1-α was increased in the 
nasopharyngeal secretions of infants with severe bronchiolitis (40) and also increased in 
preterm lambs infected with RSV (131). 
Monocyte chemotactic protein (MCP-1/CCL-2) is produced by epithelial cells and functions 
as a chemoattractant for monocytes, eosinophils, and T cells.  In vitro infection of human 
bronchiolar epithelial cells with RSV induces MCP-1 production (103, 104).  In adults with 
upper respiratory infection due to RSV MCP-1 is increased in nasal secretions during 
periods of viral shedding (99), although no publications have indicated a similar finding in 
infants.  MCP-1 is increased in term lambs infected with RSV and further increased in 
preterm lambs (beyond that of term lambs) infected with RSV (131, 132).  Increased 
expression of MCP-1 may contribute to infiltration of neutrophils and other leukocytes into 
bronchioles and the lung.  
Chemokines, such as RANTES (CCL-5) are chemotactic for T cells, dendritic cells, 
eosinophils, NK cells, mast cells, and basophils.  Contrary to its name, it is not limited to 
production by T cells; production of RANTES has been reported in platelets, macrophages, 
eosinophils, fibroblasts, endothelial, epithelial, and endometrial cells (78).  Multiple studies 
on RSV severity and human polymorphisms in RANTES have yielded conflicting results (1, 
50, 145), although an interaction or compound effect of polymorphisms at multiple sites 
yielding specific haplotypes may explain those studies in which no significance was 
demonstrated (50, 55, 58, 93, 137).  A higher ratio of IL-1 to RANTES in nasopharyngeal 
secretions of infants with RSV was associated with a more severe clinical score (53), and in 
another study there was an inverse relationship between level of RANTES in tracheal 
secretions and markers of clinical disease (120).  In vitro recombinant RANTES inhibited 
RSV infection of HEp-2 cells (30).  Low levels of RANTES in RSV infection could be due to a 
predisposed deficit or defect in RANTES production (as may be indicated by the haplotype 
studies), a direct blocking of RANTES by RSV, or indicate consumption during infection.  
RANTES is not significantly increased in term or preterm lambs infected with RSV; and PD-
L1, a negative regulator of T cell function through anergy and reduction of cytotoxicity, is 
increased in term lambs infected with RSV and further increased in preterm lambs infected 
with RSV (beyond that of term lambs) (131, 132).  Increased levels of CCL2, CCL3, CCL5 
CXCL10 are seen in infants with severe RSV bronchiolitis (46, 87).  
The cytokines and chemokines reviewed here are not exhaustive in regards to the full innate 
immune response of the lung to RSV, but emphasize repeatable findings across multiple 
studies.  Additional inflammatory mediators have potentially significant roles in innate 
defense to RSV infection; however, the current literature on their relationships to RSV is 
sparse.  Interleukin 17 (IL-17) stimulates neutrophil recruitment and stimulates fibroblasts 
and epithelial cells to secrete cytokines (95).  IL-17 was not detected among a population of 
healthy infants 1-6 months old while it was detected in 15% of RSV-infected infants in the 
same age range (71).  IL-17 levels in nasopharyngeal secretions of infants hospitalized for 
RSV was increased at discharge compared to time of admission suggesting that IL-17 may 
be involved with RSV convalescence (33).  In contrast, studies in mice studies suggest that 
IL-17 can effect regulatory T cells and contribute to increased lesions and inflammation (24, 
46).  Interferon γ-inducible protein 10 (IP10/CXCL10) is considered a marker of Th1 
response and is increased during RSV infection, although its receptor, CXCR3, is decreased 
when compared to control subjects (114).  Interleukins 19 and 20, which are related to IL-10 
and induce TNF-α and IL-6 (95), are related to a post-bronchiolitis wheeze similar to IL-10 
(32).  A polymorphism in interleukin 9 (IL-9) has an opposite effect in boys versus girls, 
associated with increased susceptibility in boys and protection in girls to severe RSV 
infection (125). 
Interleukin 21 is produced by activated CD4 T cells, natural killer T cells, T follicular helper 
cells and Th17 cells.  IL-21 induces production of inflammatory mediators from epithelial 
cells and fibroblasts and also mediates differentiation and activity of T, B, and NK cells and 
thereby restrict differentiation of regulatory T cells.  IL-21 has little effect on primary RSV 
infection in mice but in mice with RSV vaccine-enhanced disease, IL-21 reduced RSV 
disease severity and lung lesions and expression of IFN γ and IL-17 were associated with 
enhanced pathology (24).   
Effector cells of pulmonary innate immunity and effects of age 
The lung parenchyma has structural changes that occur during development and with age 
that influence innate immune responses and susceptibility to RSV and other pathogens.  
Premature infants and preterm lambs have increased RSV disease severity compared to 
healthy adults and the reason for this is not fully elucidated but likely multifactorial (23, 59, 
66, 70, 90).  The newborn has fewer alveoli that have increased wall thickness compared to 
adult alveoli.  This reduces the efficiency of gaseous exchange and may contribute to more 
severe clinical symptoms.  Submucosal glands are present in a primitive, unbranching 
structure in human respiratory airways at 13 weeks’ gestation and thereafter are present in 
more distal airways (57).  Submucosal gland expression and airway branching patterns of 
lambs are similar to those of infants (23, 122).  The number and differentiation of Clara cells 
increase in the lung during fetal and perinatal development (9, 10).  Clara cell CC10 protein 
is expressed as early as 10 weeks of gestation in humans (63), and consistently by 15 
weeks gestation (9).  Type II cells increase in number and further differentiate with fetal age 
in human and lambs (89, 108). 
The vascular endothelium serves a pivotal role in the innate-adaptive immunity interface, 
responding to innate signals to recruit and adhere to neutrophils, monocytes, dendritic cells, 
NK, NK T cells, eosinophils, basophils, and lymphocytes and also regulate the permeability 
of the vascular system to allow leakage of serum.  Serum within airways, alveoli and the 
pulmonary interstitum can dilute microbial agents and provide additional antimicrobial 
factors such as complement, antibodies, and collectins.  There is significant correlation 
between clinical severity score and total nasal wash leukocyte counts in full term but not 
preterm infants (4).   
Neutrophil infiltration into lung can occur rapidly in response to certain stimuli and release of 
inflammatory mediators and chemokines such as IL-8.  Neutrophil infiltration is a key feature 
of RSV-induced bronchiolitis.  Neutrophils of neonates have reduced proliferation pool, 
storage pool, and neutrophils in circulation have an impaired response to chemotaxins 
including reduced rolling adhesion, transmigration, and lamellipodia formation.  Neutrophils 
of infants have reduced function at the site of infection compared to adults (79).  Neutrophils 
express nearly half the level of lactoferrin, 70% of bactericidial/permeability increasing 
protein (BPI), and have impaired oxidase activity (2, 80, 110).  Preterm lambs have reduced 
levels of myeloperoxidase (131). 
Classical monocytes (CD14+, CD16-) can enter the lung to differentiate into alveolar 
macrophages whereas non-classical monocytes (CD14lowCD16-) patrol along the vascular 
lumen for antigen uptake and presentation and subsequent recruitment of neutrophils and 
classical monocytes.  Following exposure to RSV, monocytes from neonates have a more 
limited response than adults suggesting a reduced level of adaptive immune responses 
ability in the neonate (66).  In vitro stimulation of neonatal monocytes and antigen 
presenting cells have decreased expression of TNF-α, IFN-α, IFN-γ, IL-12, and IL-1β, but 
increased expression of IL-6, IL-8, and IL-10 (79).  Monocytes entering lung can differentiate 
into pulmonary alveolar macrophages (PAMs) that are thereby well-positioned to interact 
with inhaled substances.  While adult mice infected with RSV have a robust response by 
classically activated alveolar macrophages, responses are reduced in neonatal mice (31).  
Stimulation of neonatal mouse alveolar macrophages reduces RSV titers and enhanced 
weight gain (31).  Alveolar macrophages of preterm lambs have reduced levels of nitric 
oxide compared to term lambs (131).  Certain species including cattle, horse, pig, sheep, 
goat, cats, and whales have significant numbers of pulmonary intravascular macrophages 
(PIMs) (Fig. 3).  PIMs are not readily detected in human lung; however, they may be 
detected in lungs of humans with certain disease conditions such as hepato-pulmonary 
syndrome (124).   
The two major classes of dendritic cells (DCs) are myeloid DCs (mDCs) which express 
CD11c+ and plasmacytoid DCs (pDCs) which are CD11c-.  As indicated, pDCs produce 
Type I IFN, especially IFN α with lesser amounts of IFN β.  mDCs include mDC1 
(CD1c+CD141-) and mDC2 (CD1c-CD141+).  All three, mDC1, mDC2 and pDCs are 
infected by RSV and undergo maturation and cell specific cytokine production; however, 
pDCs are infected at a lower level than mDC1 and mDC2 (60).  Dendritic cells (DCs) in 
neonates are reduced in number and distribution compared to adults and the ratio of 
myeloid to plasmacytoid DCs is inversed as compared to adults.  Neonatal DCs have a 
reduced ability to produce IFN and decreased ability to stimulate a Th1 response (143).  
Dendritic cell responses of neonates to RSV have reduced activity compared to adults.  
RSV-infected DCs co-cultured with T cells of either adults or umbilical cord blood elicited 
markedly different cytokine profiles with the primary differences attributed to differences in 
response to TGF-β (138).  In mice, neonatal lungs have a deficit in conventional and 
plasmacytoid dendritic cells along with a shift of cytokines and transcription factors toward 
Th2 responses (115).  Furthermore, infecting neonatal mice with RSV results in enhanced 
TNF-α  initially followed by increased IL-13, mucus hyperproduction, and airway 
hyperreactivity (144).  Pulmonary dendritic cells isolated from term lamb lung differ from 
those isolated from adult lung in terms of antigen expression and maturation (34-36).  Ovine 
pulmonary dendritic cells from term lung support bRSV replication and have enhanced 
interleukin (IL)-4 and IL-10 gene transcripts (34-36)  
RSV and other viral infections stimulate infiltration of CD4+ and CD8+ which, along with 
DC’s and other cell types, influence Th1 and Th2 cytokines.  Formalin-inactivate RSV 
vaccines also enhance RSV disease in humans and many models.  IL-21 production in 
vaccine-enhanced RSV disease, for example, can affect regulatory T cells, reduce IL-17 and 
in this way control inflammatory responses within bronchioles, the site of RSV infection and 
lesion development (24).  These are adaptive responses reviewed elsewhere and beyond 
the scope of this review of pulmonary innate immunity (21, 46).  However, there is 
considerable overlap between the innate and adaptive immune systems in contributing and 
regulating T helper cells responses as a number of the innate factors are integral to priming 
and directing the adaptive response.  Advances in understanding innate immunity will likely 
contribute to more precise and effective adaptive responses as well as create a more 
complete picture of RSV disease and immunity.   
Discussion/conclusion 
From the above review, it is clear that the innate immune response is important in RSV 
infection, and a better understanding of it, as well as how to modulate it, could make a 
significant contribution to RSV prevention and therapy in infants.  Enhancement of innate 
immune responses may reduce RSV disease severity or prevent initial infection.  Also, 
because many innate immune responses stimulate adaptive immune responses, enhanced 
activation of innate immune responses may bolster/strengthen adaptive responses.  Innate 
immune responses require some level of lung maturation and activity of single cell types in 
some cases (e.g., surfactant protein A production by type II cells) or several cell types 
(epithelial and submucosal glands for Duox/LPO oxidative defense) (37, 38).  Enhancement 
of pulmonary maturation may bolster innate responses and studies in lambs have 
demonstrated that vascular endothelial growth factor (VEGF) administration intratracheally 
prior to RSV infection reduces disease severity (92, 102).  VEGF expression by 
development lung is vital for maturation and differentiation and exogenously administer 
VEGF up-regulates SP-A, induces monocyte infiltration, and can contribute to vascular leak 
(102).  Thus, therapies such as VEGF may activate aspects of the innate immune response 
and simultaneously trigger other defense mechanisms with potential enhancement of 
adaptive responses.  There are also novel genetic vaccines, microparticles, therapies 
targeting the RSV receptor, L-polymerase inhibitors, therapies that promote enhancement of 
TLR4 signaling intensity, therapies that target of the recently discovered RSV receptor, 
nucleolin and many others giving hope for effective prophylactic and therapeutic strategies. 
Despite what is known about pulmonary innate immune responses to virus such as RSV by 
the neonatal lung there is much to be learned.  Many cellular mechanisms of innate immune 
products have yet to be fully defined in the newborn respiratory tract, including:  inhibitory 
RNA (iRNA) regulation of innate immune gene expression, expression and down-regulation 
of innate immune gene receptors by the various cell types, the extent to which immature or 
poorly differentiated cells can produce innate immune products, and the extent to which 
sequestration of inflammatory and innate immune mediators by extracellular matrix 
proteoglycans differs in newborn versus adult respiratory tract.   
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 Table 1.  Antimicrobial products from epithelia of the respiratory airways and alveoli that 
contribute to innate defense (Adapted from 118; Schutte, McCray, β-defensins in lung host 
defense.  Annu Rev Physiol 64:709-748, 2002). 
 
Product Source Activity 
Lysozyme epithelia, neutrophils, 
macrophages 
Microbicidal 
Lactoferrin epithelia, neutrophils Iron sequestration 
Secretory leukocyte protease 
inhibitor (SLPI) 
epithelia, macrophages Microbicidal, anti-
protease 
IgA secretory component epithelia Opsonization 
Phospholipase A2 (PLA2) epithelial, neutrophils Microbicidal 
Surfactant protein A (SP-A) epithelia Opsonizes and 
aggregates RSV, 
activates macrophages 
Surfactant protein D (SP-D) epithelia Opsonizes and 
aggregates RSV, 
activates macrophages 
Defensins (α, β, θ) epithelia, neutrophils, 
macrophages 
Microbicidal, leukocyte 
activation, dendritic cell 
chemotaxis 
Cathelicidins neutrophils, epithelia Microbicidal 
Anionic peptide epithelia Microbicidal 
RNAase 7 epithelia Microbicidal 
Bacterial/permeability increasing 
(BPI) protein 
neutrophils, epithelia Microbicidal, 
lipopolysaccharide 
binding 
Lactoperoxidase submucosal glands Conversion of 
hydrogen peroxide to 
microcidal halide 
Duox (Dual functioning oxidase) epithelia Formation of hydrogen 
peroxide 
Clara cell specific 10 kD protein 
(CC10) (secretoglobin, 
uetroglobin) 
Clara cells Immunomodulation 
Palate, lung, and nasal epithelium 
(PLUNC) 
epithelia Microbicidal, LPS 
binding, function not 
fully understood 
Lipocalin; neutrophil gelatinase-
associated lipocalin (NGAL) 
epithelia Siderophore binding, 
function not fully 
understood 
 
  
Table 2.  Innate immune features of the respiratory tract of infants/neonates and responses 
to respiratory syncytial virus (RSV). 
Innate Immune component Feature in infants/neonates  Reference 
Mucin production  Epithelial and goblet cells 
and submucosal glands 
differentiate progressively 
with respiratory tract 
development; TLR7, IL-17, 
IL-23 regulate mucin 
production in response to 
RSV infection 
57, 85, 89 
Ciliary beat frequency Differences between 
neonates and adults not fully 
known 
 
Dual functioning oxidases 
and lactoperoxidase 
Slight increased activity at 3 
weeks of age compared to 
newborn lung 
Manuscript in preparation 
Surfactant proteins A and D Polymorphism associated 
with severe disease in 
infants; Differential 
expression by preterm and 
term lung with RSV infection; 
Reduced in infants with 
severe RSV;  Increased 
production with development 
3, 61, 62, 91, 133 
Defensins, cathelicidins. 
antimicrobial peptides, 
antimicrobial proteins 
(PLUNC, lipocalin)  
Differential expression by 
preterm and term lung with 
RSV infection; Increased 
production by epithelia with 
development 
52, 61, 90, 118, 133 
Clara cell CC10 production Increases with development 9, 10, 108, Figure 2 
Type II cell formation Increased differentiation with 
pulmonary development  
16, 89, 139 
Proteoglycans and 
glycosaminoglycans of the 
extracellular matrix 
Sequester chemokines, 
cytokines, and growth factors 
in a latent form that can be 
released with enzymatic 
42 
digestion 
Toll-like receptor (TLR) 
expression 
TLR 4 polymorphisms 
associated with severe 
disease in infants; Increased 
expression of TLR 3, 4 7 and 
8 differentially expressed 
with development 
7, 91, 109, 116, 133 
Retinoic acid-inducible gene I 
(RIG-I) 
Differences in expression 
between neonates and 
adults is not fully known.  
RIG-I is triggered by RSV 
infection 
 
Interferon α and β Reduced expression/activity 
mediated by the RSV 
proteins NS1 and NS2 
123, 135 
Interferon-γ IFN-γ is low in secretions of 
infants and enhances activity 
of immature alveolar 
macrophage and RSV 
clearance 
31, 127 
Interleukin-1 High IL-1 and low RANTES 
are associated with more 
severe clinical scores in 
infants; IL-1β levels are 
associated with severe 
disease in infants 
53, 84, 88 
Tumor necrosis factor α  Increased TNF α in infants 
with severe RSV bronchiolitis 
and in preterm lambs 
88, 131 
Interleukin-8 Increased with disease 
severity in infants; not 
detected in preterm infants in 
one study 
14, 73 
Interleukin-10 Increased with RSV infection 
in infants 
94 
Transforming growth factor-β Inhibits CD4+ cell 
proliferation and 
132 
differentiation in infants 
Macrophage inflammatory 
protein-1 α  
Increased in infants and 
lambs with bronchiolitis 
41, 131 
Regulated on Activation 
Normal T cells Expressed 
and Secreted (RANTES) 
RANTES polymorphisms 
associated with severe RSV 
disease; High IL-1 and low 
RANTES associated with 
more severe clinical scores 
1, 50, 53, 103 
CCL2, CCL3, CCL5 CXCL10 Increased chemokine 
expression with severe RSV 
bronchiolitis 
87 
Interleukin-17 IL-17 increased with RSV 
convalescence; IL-17 
mediates mucin production; 
IL-17 contributes to RSV 
pathology in vaccine-
enhanced model 
24, 33, 87 
Interleukin-21 IL-21 has little effect on 
primary RSV infection but 
reduces RSV disease 
severity in vaccine-induced 
enhanced disease model 
24, 46 
Neutrophils Neonates have reduced 
proliferation pool, 
chemotactic responses, 
rolling, transmigration, 
lamellopodia, oxidate activity, 
lactoferrin and 
myeloperoxidase 
2, 79,80, 110 
Monocytes Reduced cytokine 
responses; IFN gamma 
enhances RSV clearance 
31, 66, 79 
Dendritic cells Reduced numbers of DCs in 
neonates and reduced 
plasmacytoid DC to myeloid 
DCs in neonates compared 
to adults, altered cytokine 
profiles, reduced antigen 
expression and maturation; 
34-36, 115, 138, 142 
neonatal DC favor Th2 shift 
 
  
Fig. 1.  Schematic illustration depicting some of the innate immune systems of the lung 
airways and alveoli.  (This image was drawn by Ackermann and published in:  Ackermann 
MR, Derscheid RM, Roth JA. VCNA 26:215-228, 2010)   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Fig. 2.  Expression of CC10 in lung of lambs during ontogeny.  CC10 mRNA levels in 
preterm lung are very low in fetal lung and increase progressively with age (manuscript in 
preparation).  Susceptibility to RSV is increased in preterm infants (and lambs) and reduces 
expression of innate immune products, such as CC10 may underlie the increased 
susceptibility to RSV infection.  For each timepoint, n = 4 lambs/group and RNA levels were 
determined by RT-qPCR using 0.784 ng RNA/µl per sample and assessing levels to a Stock 
I-derived standard curve for CC10 and results were normalized to total lung RNA loaded RT-
qPCR.  Results were assessed by GraphPad Prism 6 with a one-way ANOVA followed by 
Tukey’s post-test. 
 
 
 
 
  
 Fig. 3.  Lung, calf.  Pulmonary alveolar macrophages (brown, stained with CD68) within 
alveolar lumens where they are positioned well for responsiveness to stimuli entering the 
alveolar lumen.  Alveolar blood vessels are congested but along the endothelial area are 
small regions of staining which may be due to pulmonary intravascular macrophages.  
Immunohistochemistry stain to CD68 antigen (Dako, primary antibody); Hematoxlyn 
counterstain.  40X.  (This image is from Ackermann and published in:  Ackermann, et al Vet 
Pathol 31:340-348, 1994). 
 
 
